Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00203463 · ClinicalTrials.gov registry record · Phase 4

Topiramate in the Treatment of Post Traumatic Stress Disorder (PTSD)

A Phase 4 study of PTSD, sponsored by Tuscaloosa Research & Education Advancement Corporation.

Completed
Registry status
Phase 4
Development phase
40
Enrollment target
1
Study location

NCT00203463 is a Phase 4 study of PTSD that has completed, run by Tuscaloosa Research & Education Advancement Corporation. The registered enrollment target is 40 participants, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00203463, a Phase 4 study of PTSD, has completed, sponsored by Tuscaloosa Research & Education Advancement Corporation.

COMPLETED
Registry status
Phase 4
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

To study the potential therapeutic effects of topiramate (Topamax) in the treatment of PTSD.

Conditions Studied

Interventions

  • DRUG topiramate

Study Locations (1)

Alabama

  • Tuscaloosa Research & Education Advancement Corporation - Tuscaloosa

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2001-07
Est. Completion 2004-09
Phase Phase 4

What the Registry Record Tells You About NCT00203463

The ClinicalTrials.gov registry entry for NCT00203463 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (87% lower). The listed sponsor is Tuscaloosa Research & Education Advancement Corporation, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with PTSD appearing as the primary indexed condition, and to 1 intervention - of which topiramate is the first listed.

NCT00203463 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.

Frequently Asked Questions

What is clinical trial NCT00203463 about?

NCT00203463 is a clinical study titled "Topiramate in the Treatment of Post Traumatic Stress Disorder (PTSD)". To study the potential therapeutic effects of topiramate (Topamax) in the treatment of PTSD.

What is the current status of trial NCT00203463?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2001-07. Estimated completion is 2004-09.

What conditions does trial NCT00203463 study?

This clinical trial studies the following conditions: PTSD.

What interventions are being tested in trial NCT00203463?

The interventions under investigation include: topiramate (DRUG).

Who is sponsoring clinical trial NCT00203463?

This trial is sponsored by Tuscaloosa Research & Education Advancement Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00203463 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for PTSD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.